NCT00306618View on ClinicalTrials.gov

Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

December 31, 2008

Conditions
Recurrent Glioblastoma Multiforme
Interventions
DRUG

Panzem Nanocrystal Colloidal Dispersion

Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing

Trial Locations (1)

27710

The Brain Tumor Center, Duke University Medical Center, Durham

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY